This webinar presents pooled long‑term data from men treated with stereotactic body radiotherapy (SBRT) for prostate cancer, with follow‑up beyond 10 years. It reviews the current evidence supporting SBRT, highlighting excellent oncological outcomes and low toxicity. A key focus is PSA kinetics after SBRT, exploring their relationship with biochemical relapse and clinical recurrence using long‑term institutional and published data. The session also examines the expanding role of SBRT in oligometastatic prostate cancer, including treatment of metastatic lesions to improve disease control.